Quantcast
Last updated on April 18, 2014 at 7:49 EDT

Latest Tardive dyskinesia Stories

2008-10-28 06:00:28

By Rita Rubin Baylor College of Medicine neurologist Joseph Jankovic is a patient man. With the Food and Drug Administration's OK, Jankovic has studied the drug tetrabenazine since 1979. Over the years, he estimates, he has dispensed tetrabenazine -- or TBZ, as he calls it -- to 1,000 people with Huntington's disease, probably more than any doctor in the world. Tetrabenazine helps tame the uncontrollable movements, or "chorea," that characterize Huntington's, an inherited...

2008-09-26 06:00:12

INDIANAPOLIS, Sept. 26 /PRNewswire-FirstCall/ -- The Committee for Medicinal Products for Human Use (CHMP) has recommended European approval of Olanzapine Long-acting Injection (LAI), known in Europe by the trade name Zypadhera(TM), for maintenance treatment of adult patients with schizophrenia sufficiently stabilized during acute treatment with oral olanzapine, Eli Lilly and Company (LLY) announced today. The CHMP's positive opinion is now referred for final action to the European...

2008-09-17 09:00:14

OVATION Pharmaceuticals, Inc. announced today that it has acquired from Prestwick Pharmaceuticals the exclusive license in the United States to commercialize Xenazine(R) (tetrabenazine), an orphan drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of chorea associated with Huntington's Disease (HD). Financial terms of the deal were not disclosed. Subsequently, Biovail Corporation, Canada's largest publicly traded pharmaceutical company, acquired Prestwick....

2008-08-18 12:00:56

Prestwick Pharmaceuticals has announced that the FDA has approved Xenazine for the treatment of chorea associated with Huntington's disease. Xenazine is said to be the first and only FDA-approved treatment for any symptom of Huntington's disease (HD) and is expected to be available later 2008. A double-blind, placebo-controlled, Phase III study found that Xenazine significantly reduced patients's chorea burden, improved global outcome scores, and was generally safe and well tolerated....

891e7e55db7a0b85faf798c8b9fbf9411
2008-08-18 12:05:00

The U.S. Food and Drug Administration announced approval of Xenazine (tetrabenazine) for the treatment of chorea in people with Huntington's disease. The FDA said Xenazine is a new drug and the first treatment of any kind approved in the United States for any symptom of Huntington's disease. Currently there are no other drugs that are FDA-approved to treat chorea -- the jerky, involuntary movement that occurs in people with the disease. The federal agency said side effects reported with use...

2008-08-15 18:00:26

NEW YORK, Aug. 15 /PRNewswire/ -- The Hereditary Disease Foundation (HDF) is extremely pleased the U.S. Food and Drug Administration has approved Xenazine, or tetrabenazine, for the treatment of chorea associated with Huntington's disease. "Chorea is a major cause of disability and death in patients with Huntington's disease. Chorea is not just a mere inconvenience; it can prevent Huntington's disease patients from walking, talking, working, watching television and almost every aspect of...

2008-08-15 15:00:14

WASHINGTON, Aug. 15 /PRNewswire/ -- Prestwick Pharmaceuticals, Inc., a privately-held pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved XENAZINE(R) (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). XENAZINE is the first and only FDA-approved treatment for any symptom of HD and is expected to be available later this year. "Until today, physicians and patients had no FDA-approved treatments for...

2007-05-22 15:00:49

SAN DIEGO, May 22 /PRNewswire/ -- After administration of paliperidone extended-release (ER) tablets, blood levels of the drug were not affected when given with a common antidepressant, according to new data presented today at the 160th Annual Meeting of the American Psychiatric Association. Paroxetine, a selective serotonin reuptake inhibitor (SSRI), is an antidepressant known to interact with several antipsychotic medications. This new study showed there was no clinically significant...

2005-08-05 09:48:48

WASHINGTON (Reuters) - Pozen Inc. said on Friday it would no longer pursue U.S. approval of its experimental migraine drug MT 100, one day after a U.S. advisory panel said another clinical trial was needed. Regulators had rejected the drug in May 2004 over concerns about the risk of users developing unusual tongue and mouth movements. MT 100 aimed to help migraine patients who do not have nausea. Instead, the North Carolina-based drugmaker said it will continue pursuing its other headache...